A traditional Chinese medicine composition for preventing and treating hyperlipidemia, its preparation method and uses

Abstract

The present invention belongs to the field of traditional Chinese medicine, and relates to a traditional Chinese medicine composition for preventing and treating hyperlipidemia, as well as its method and use. The traditional Chinese medicine composition is made from the following raw medicinal materials in parts by weight: 10 - 60 parts of Paederia scandens, 5 - 40 parts of Atractylodes lancea, 5 - 40 parts of Hawthorn Fruit, 5 - 40 parts of White Peony Root, and 5 - 30 parts of Honeysuckle Flower. The traditional Chinese medicine composition of the present invention has the effects of promoting blood circulation and nourishing blood, strengthening the spleen and resolving turbidity. Experimental studies show that the traditional Chinese medicine composition of the present invention has the functions of reducing blood lipid, anti-inflammatory, and improving liver function, can effectively prevent and treat hyperlipidemia, and has good safety.

Description

Technical Field

[0001] The present invention belongs to the field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for preventing and treating hyperlipidemia, a preparation method thereof, and uses thereof. Background Art

[0002] Hyperlipidemia is a lipid metabolism disorder disease caused by various reasons, characterized by elevated levels of total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) and / or decreased levels of high-density lipoprotein cholesterol (HDL-C) in serum. Clinical studies have shown that hyperlipidemia is one of the main risk factors leading to atherosclerosis and then ischemic cardiovascular and cerebrovascular diseases.

[0003] Hyperlipidemia is divided into primary and secondary types. Primary hyperlipidemia has a familial tendency, manifested as familial hypercholesterolemia, clinically characterized by elevated LDL-C, with an incidence of about 0.28%. Secondary hyperlipidemia is abnormal blood lipid caused by other diseases, such as diabetes, hypertension, etc. In addition, age, body weight, and some lifestyles such as diet, exercise, and mental stress can also affect blood lipid levels. Hyperlipidemia mostly endangers arteries, the heart, the brain, the skin, etc., and the clinical manifestations mainly include xanthoma, premature corneal arcus, fundus changes, and arteriosclerosis, etc.

[0004] Modern medical research on the pathogenesis of hyperlipidemia mainly focuses on aspects such as excessive intake of lipids or sugars, abnormalities of hormones (insulin, thyroid hormone) and metabolism (glucose metabolism), genetic defects, etc. Clinically, the drugs for treating hyperlipidemia mainly include statins, fibrates, niacin, ezetimibe, Ω-3 polyunsaturated fatty acids, bile acid sequestrants, etc. Although certain curative effects have been achieved in the treatment of hyperlipidemia, the adverse reactions are also relatively obvious.

[0005] Traditional Chinese medicine has certain advantages in the treatment of hyperlipidemia, and more and more studies have used traditional Chinese medicine to prevent and treat hyperlipidemia. Traditional Chinese medicine believes that phlegm turbidity and stasis blood are the main causes of hyperlipidemia. Overeating fatty, sweet, and thick-flavored foods damages the spleen. When the spleen is damaged, the transportation and transformation of essence, qi, blood, and body fluids are abnormal, condensing into phlegm, and over time, turning into stasis. The endogenous phlegm turbidity, stasis blood, and endogenous turbidity toxin ultimately form turbid lipids. Phlegm turbidity and stasis blood are not only the initiating factors for the generation of "exuberant fire", but also the aggravating factors leading to spleen deficiency ("consuming qi"). Therefore, under the guidance of the theory of "exuberant fire consuming qi", the main treatment principles of strengthening the spleen and resolving phlegm, reducing turbidity and removing stasis have gradually formed. However, it has been found in the treatment practice that the traditional Chinese medicine composition designed according to this treatment principle has unsatisfactory effects.

[0006] Therefore, it is still necessary to study different traditional Chinese medicine compositions according to the pathogenesis of hyperlipidemia in order to develop new traditional Chinese medicine compositions for preventing and treating hyperlipidemia that have definite curative effects, are safe and have appropriate prices. Summary of the Invention

[0007] In order to overcome the problem that the traditional Chinese medicine compositions for preventing and treating hyperlipidemia with the treatment principle of "invigorating the spleen and resolving phlegm, reducing turbidity and removing stasis" are not ideal in effect, the present invention first adopts the treatment method of "activating blood circulation and nourishing blood, invigorating the spleen and resolving turbidity", and provides a traditional Chinese medicine composition for preventing and treating hyperlipidemia that has definite curative effects, is safe and has appropriate prices.

[0008] The first aspect of the present invention:

[0009] The present invention provides a traditional Chinese medicine composition for preventing and treating hyperlipidemia, and the traditional Chinese medicine composition is made from the following raw materials in parts by weight: 10-60 parts of Paederia scandens, 5-40 parts of Atractylodes lancea, 5-40 parts of Hawthorn Fruit, 5-40 parts of White Peony Root, 5-30 parts of Honeysuckle Flower.

[0010] Preferably, the traditional Chinese medicine composition is made from the following raw materials in parts by weight: 15-50 parts of Paederia scandens, 10-30 parts of Atractylodes lancea, 10-30 parts of Hawthorn Fruit, 10-30 parts of White Peony Root, 10-20 parts of Honeysuckle Flower.

[0011] Preferably, the traditional Chinese medicine composition is made from the following raw materials in parts by weight: 15 parts of Paederia scandens, 10 parts of Atractylodes lancea, 10 parts of Hawthorn Fruit, 10 parts of White Peony Root, 10 parts of Honeysuckle Flower.

[0012] Preferably, the traditional Chinese medicine composition is made from the following raw materials in parts by weight: 30 parts of Paederia scandens, 20 parts of Atractylodes lancea, 20 parts of Hawthorn Fruit, 20 parts of White Peony Root, 15 parts of Honeysuckle Flower.

[0013] Preferably, the traditional Chinese medicine composition is made from the following raw materials in parts by weight: 50 parts of Paederia scandens, 30 parts of Atractylodes lancea, 30 parts of Hawthorn Fruit, 30 parts of White Peony Root, 20 parts of Honeysuckle Flower.

[0014] Preferably, the traditional Chinese medicine composition has the effects of activating blood circulation and nourishing blood, invigorating the spleen and resolving turbidity.

[0015] The second aspect of the present invention:

[0016] The present invention provides the use of the traditional Chinese medicine composition described in the first aspect above in the preparation of a drug.

[0017] Preferably, the use is for the preparation of a drug for preventing and treating hyperlipidemia.

[0018] Preferably, the drug has the effects of reducing blood lipid, anti-inflammatory and improving liver function.

[0019] Preferably, the drug has good safety, no liver and kidney toxicity, and can be taken for a long time.

[0020] Preferably, the drug is in solid form, semi-solid form or liquid form.

[0021] Preferably, the drug is decoction, granule, paste, tablet, capsule, oral liquid, powder or cut crude drug.

[0022] Preferably, in the above uses, the drug is decoction or granule.

[0023] The third aspect of the present invention:

[0024] The drug of the present invention can be prepared by conventional preparation methods in the art, and pharmaceutically acceptable excipients can be optionally added or not added. As long as the traditional Chinese medicine raw materials are in the above weight parts, regardless of various changes in its preparation methods, they all belong to the scope of the present invention. Its drug forms include but are not limited to solid form, semi-solid form or liquid form, etc.; specifically include but are not limited to decoction, granule, paste, tablet, capsule, oral liquid, powder or cut crude drug.

[0025] Preferably, it includes extracting the traditional Chinese medicine composition, such as decoction extraction, reflux extraction, ultrasonic extraction, etc.

[0026] Preferably, it includes weighing each raw material drug, pre-treatment, extraction (water and / or alcohol), and concentration.

[0027] Preferably, it includes weighing each raw material drug, pulverizing, extracting, and concentrating.

[0028] Preferably, the extraction method is decoction, and / or the extraction solvent is water or ethanol, and / or the number of decoction times is 1-3 times, and / or the decoction time for each time is 1-3 hours.

[0029] Preferably, water extraction is used.

[0030] The formula analysis of the traditional Chinese medicine composition of the present invention is as follows:

[0031] Hyperlipidemia, also known as lipid metabolism disorder or abnormality, refers to a metabolic disease in which one or more lipid levels in plasma, such as total cholesterol, triglyceride and low-density lipoprotein cholesterol, increase or high-density lipoprotein cholesterol decreases due to various reasons, and it is also a high-risk factor for atherosclerosis of important target organs such as the heart and brain.

[0032] Therefore, this prescription is composed of Paederia scandens, Atractylodes lancea, Crataegus pinnatifida, Paeonia lactiflora, and Lonicera japonica. The whole prescription has the effects of promoting blood circulation and nourishing blood, strengthening the spleen and resolving turbidity. Among them, Paederia scandens is the monarch drug, which has the functions of promoting digestion and strengthening the stomach, resolving phlegm and detoxifying; Atractylodes lancea strengthens the spleen and resolves dampness, and Crataegus pinnatifida promotes digestion and strengthens the stomach. The spleen and stomach are the source of the generation of fat turbidity. Atractylodes lancea and Crataegus pinnatifida can clear and transport the spleen and stomach, reduce lipid and resolve turbidity, and they are the ministerial drugs together; Paeonia lactiflora can nourish blood and promote blood circulation, astringe yin, and Lonicera japonica can clear heat and detoxify. The two are the assistant drugs together, achieving the effect of clearing the heat toxin in the blood without damaging yin. The compatibility of the whole prescription together achieves the effects of promoting blood circulation and nourishing blood, strengthening the spleen and resolving turbidity, thereby removing the turbid fat in the blood vessels.

[0033] "Paederia scandens" is the whole herb and root of the plant Paederia scandens (Lour.) Merr of the Rubiaceae family. It is sweet, slightly bitter, and flat. It has the effects of promoting digestion and strengthening the stomach, resolving phlegm and relieving cough, clearing heat and detoxifying, and relieving pain. It is used for food retention, infantile malnutrition, heat phlegm cough, heat toxin dysentery, sore throat, carbuncles and boils, scalds and burns, various pain syndromes, eczema, neurodermatitis, skin pruritus, etc.

[0034] "Atractylodes lancea" is the dried rhizome of the plant Atractylodes lancea (Thunb.) DC. or Atractylodes chinensis (DC.) Koidz. of the Compositae family. It is pungent, bitter, and warm. It has the functions of drying dampness and strengthening the spleen, expelling wind and cold, and improving eyesight. It is mainly used for dampness blocking the middle jiao, abdominal distension, diarrhea, edema, beriberi with flaccidity, rheumatic arthralgia, wind-cold cold, night blindness, and dim and blurred eyes.

[0035] "Crataegus pinnatifida" is the dried ripe fruit of the plant Crataegus pinnatifida Bge. var. major N.E.Br. or Crataegus pinnatifida Bge. of the Rosaceae family. It is sour, sweet, and slightly warm. It promotes digestion and strengthens the stomach, promotes qi movement and dispels stasis, and reduces lipid turbidity. It is used for meat retention, abdominal distension in the stomach cavity, diarrhea and dysentery with abdominal pain, stasis of blood in menstruation obstruction, postpartum stasis obstruction, pain in the heart and abdomen, chest impediment pain, hernia pain, hyperlipidemia. Stir-fried Crataegus pinnatifida has enhanced effect of promoting digestion and guiding out stagnation. It is used for meat retention and unsmooth diarrhea and dysentery.

[0036] "Paeonia lactiflora" is the dried root of the plant Paeonia lactiflora Pall. of the Ranunculaceae family. It is bitter, sour, and slightly cold. It nourishes the liver and softens the liver, soothes the middle and relieves pain, and astringes yin and stops sweating. It is used to treat pain in the chest, abdomen, hypochondrium and costal region, diarrhea and dysentery with abdominal pain, spontaneous sweating and night sweating, yin deficiency fever, irregular menstruation, metrorrhagia and metrostaxis, and leukorrhea.

[0037] "Lonicera japonica" is the dried flower bud or flower with the first bloom of the plant Lonicera japonica Thunb. of the Caprifoliaceae family. It is sweet, cold, and has the effects of clearing heat and detoxifying, reducing inflammation and subsiding swelling. It is mainly used for exogenous wind-heat or febrile disease with fever, heat stroke, heat toxin dysentery, carbuncles and boils, sore throat, and various infectious diseases.

[0038] The present invention has the following beneficial effects compared with the prior art:

[0039] (1) The present invention first adopts the treatment method of activating blood circulation and nourishing blood, strengthening the spleen and resolving turbidity, and can effectively prevent and treat hyperlipidemia.

[0040] (2) The results of pharmacological experimental studies show that the traditional Chinese medicine composition of the present invention has the effects of reducing blood lipid, anti-inflammatory, and improving liver function.

[0041] (3) The traditional Chinese medicine composition of the present invention has good safety, no liver and kidney toxicity, and can be taken for a long time. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] Figure 1 ∶ Representative photograph of the effect of the traditional Chinese medicine composition of the present invention on the gross oil red staining of the aorta (magnification X1).

[0043] Figure 2 ∶ Representative photograph of the effect of the traditional Chinese medicine composition of the present invention on the oil red O staining of the liver (magnification X200). DETAILED DESCRIPTION OF THE INVENTION

[0044] The present invention will be further described below with reference to specific embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the scope of the present invention.

[0045] For those not specifying specific techniques or conditions in the embodiments, the techniques or conditions described in the literature in this field or according to the product specifications are followed. For reagents or instruments not indicating the manufacturer, they are all conventional products that can be obtained through regular channels.

[0046] The experimental methods in the following examples are all conventional methods unless otherwise specified. The test materials used in the following examples are all commercially available products unless otherwise specified.

[0047] Preparation Example:

[0048] Example 1∶

[0049] Paederia scandens 15g, Atractylodes lancea 10g, Hawthorn 10g, White peony root 10g, Honeysuckle 10g

[0050] Total amount: 55g

[0051] All the drugs are pulverized into fine powder, added with 1000 mL of distilled water for decoction. After the first decoction for 1.5 hours, the first filtrate is obtained by filtration. The residue is added with 1000 mL of distilled water and decocted for 1.5 hours, and the second filtrate is obtained by filtration. The first filtrate and the second filtrate are combined and concentrated under reduced pressure to obtain 300 mL of concentrated solution.

[0052] Example 2:

[0053] 50 g of Paederia scandens, 30 g of Atractylodes lancea, 30 g of Hawthorn Fruit, 30 g of White Peony Root, 20 g of Honeysuckle Flower

[0054] Total amount: 160 g

[0055] The preparation method is the same as that of Example 1.

[0056] Comparative Example 1:

[0057] 15 g of Millettia reticulata, 10 g of Atractylodes lancea, 10 g of Hawthorn Fruit, 10 g of White Peony Root, 10 g of Honeysuckle Flower

[0058] Total amount: 55 g

[0059] The preparation method is the same as that of Example 1.

[0060] Comparative Example 2:

[0061] 10 g of Atractylodes lancea, 10 g of Hawthorn Fruit, 10 g of White Peony Root, 10 g of Honeysuckle Flower, 10 g of Forsythia suspensa

[0062] Total amount: 50 g

[0063] The preparation method is the same as that of Example 1.

[0064] Comparative Example 3:

[0065] 36 g of Paederia scandens, 18 g of Atractylodes lancea

[0066] Total amount: 54 g

[0067] The preparation method is the same as that of Example 1.

[0068] Comparative Example 4:

[0069] 33 g of Hawthorn Fruit, 22 g of White Peony Root

[0070] Total amount: 55 g

[0071] The preparation method is the same as that of Example 1.

[0072] Positive drug group:

[0073] Xuezhikang: Purchased from Peking University Weixin Biotechnology Co., Ltd., with the national drug approval number Z10950029. Dissolve Xuezhikang capsules in physiological saline and convert the dosage for intragastric administration in golden hamsters according to the amount of 4 capsules per day for adults.

[0074] Effect Example: Pharmacodynamic study of the traditional Chinese medicine composition of the present invention for preventing and treating hyperlipidemia

[0075] 1. Preparation for establishing an animal model of hyperlipidemia:

[0076] One hundred and eight SPF-grade male golden hamsters, 6-8 weeks old, weighing (90±10) g, were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd., with the animal production license number: SCXK (Beijing) 2016-0011. They were housed in the animal experiment center of Beijing Liaoweiyuan Medical Technology Co., Ltd., with the license number: SYXK (Beijing) 2022-0007, at a temperature of (22±2) °C, a humidity of (50±10)%, and a 12h light / dark cycle. The animals had free access to food and water. The high-fat diet was provided by Beijing Xiaoshu Youtai Biotechnology Co., Ltd., with the license number: SCXK (Beijing) 2018-0006. The high-fat diet formula: 10% lard, 5% sucrose, 2% cholesterol, 0.5% sodium cholate, 82.5% basal diet.

[0077] 2. Modeling, grouping and drug administration of animals

[0078] After 3 days of adaptive feeding, 9 golden hamsters were used as the control group and were fed with conventional maintenance feed throughout the experiment. Ninety-nine golden hamsters were fed with a high-fat diet. After 8 weeks of modeling, 3 golden hamsters were randomly selected from the control group and the model group for sampling. Oil red O staining of the aorta showed that there was lipid deposition in the aortic intima of the golden hamsters in the model group, indicating that the in vivo model of hyperlipidemia was successfully established.

[0079] After modeling, the golden hamsters were randomly divided into 8 groups: the model group, Example 1 group, Example 2 group, Comparative Example 1 group, Comparative Example 2 group, Comparative Example 3 group, Comparative Example 4 group, and positive drug group, with 12 golden hamsters in each group, and continued to be fed with a high-fat diet. Except for the model group, while all the medicated groups of golden hamsters were fed with a high-fat diet, they were given corresponding drugs by gavage (at a dose of 1 mL / rat / day); the control group and the model group were given an equal volume of normal saline by gavage to ensure consistency between groups. Gavage was performed once a day for 8 consecutive weeks. The specific intervention measures are shown in Table 1 below:

[0080] Table 1: Drug administration scheme used in this experiment

[0081]

[0082]

[0083] 3. Collection of serum and tissue specimens

[0084] After the last drug administration, the animals were fasted for 12 h without water restriction. They were anesthetized intraperitoneally with 3% pentobarbital sodium, and blood was taken from the jugular vein. The blood was allowed to stand at room temperature for 30 min, then at 4 °C for 2 h, and centrifuged at 4000 r / min at 4 °C for 10 min to separate the upper serum, which was stored at -80 °C. After blood collection, the chest and abdomen of the golden hamsters were opened, and the aorta from the aortic root to the bifurcation of the common iliac artery was dissected as a whole, and the surrounding redundant connective tissue and adipose tissue were removed, and then put into liquid nitrogen or tissue fixative for preservation for subsequent related experiments.

[0085] 4. Effect index test

[0086] (1) Detect the blood lipid levels and liver function-related indexes in the serum of golden hamsters by enzyme-linked immunosorbent assay (ELISA)

[0087] Use an automatic biochemical analyzer to detect the levels of total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (γ-GT), albumin (ALB), and alkaline phosphatase (ALP) in the serum of golden hamsters.

[0088] (2) Detect the serum inflammatory factor levels by ELISA

[0089] Operate according to the ELISA kit instructions to detect the levels of transforming growth factor-β (TGF-β), interleukin-4 (IL-4), and tumor necrosis factor-α (TNF-α) in the serum of golden hamsters.

[0090] (3) Determine the overall aortic plaque area by gross oil red O staining

[0091] Fix the longitudinal section of the aorta of golden hamsters under an optical microscope, wash it with water, stain it with oil red O, lay the blood vessel flat on a black rubber plate, take a quick photo, and use Image J software to analyze the relative plaque area of the aorta to evaluate the severity of aortic plaques. Relative plaque area (%) = aortic intimal plaque area / total blood vessel area × 100%. (4) Evaluate the pathological morphology of the liver of golden hamsters by oil red O staining

[0092] Take tissue blocks (0.5 cm × 1.0 cm in size) from the same part of the liver and immerse them in 10% neutral formalin fixative to fix the tissue proteins and make them denature and coagulate. After 24 hours, replace the fresh 10% neutral formalin fixative; dehydrate with gradient ethanol and make it transparent in xylene, and perform paraffin and OCT embedding respectively. For the OCT-embedded liver samples, perform frozen sectioning, perform tissue oil red O staining, observe the liver morphology under a light microscope, and use ImageJ image processing software to analyze the oil red O staining area.

[0093] 5. Statistical methods

[0094] Use GraphPad Prism 8.0 for statistical analysis and statistical plotting. The experimental results are presented as Representation. One-Way ANOVA analysis was used for the comparison of means among multiple groups, and a P value < 0.05 was considered statistically significant.

[0095] 6. Results

[0096] (1) Gross oil red O staining of aorta

[0097] The gross oil red O staining results of the aorta showed that, compared with the model group, both Example 1 and Example 2 groups could reduce the overall plaque area of the aorta. The results are as Figure 1 shown in Table 2.

[0098] Table 2: Proportion of aortic plaques in golden hamsters ( n = 3) %

[0099]

[0100] * P < 0.05 compared with the control group; △ P < 0.05 compared with the model group

[0101] (2) Oil red O staining of liver

[0102] The oil red O staining results of the liver showed that, compared with the model group, both Example 1 and Example 2 could reduce the lipid droplet area of the liver. The results are as Figure 2 shown in Table 3.

[0103] Table 3: Proportion of lipid droplet area in golden hamster liver ( n = 3) %

[0104]

[0105]

[0106] * P < 0.05 compared with the control group; △ P < 0.05 compared with the model group

[0107] (3) Blood lipid levels

[0108] Regarding blood lipid levels, TC, TG, LDL-C, and HDL-C were measured. The research results showed that, compared with the model group, both Example 1 and Example 2 could reduce the levels of TC, TG, and LDL-C in golden hamsters. The results are shown in Table 4.

[0109] Table 4: Serum lipoprotein levels in golden hamsters ( n = 6) mmol / L

[0110]

[0111]

[0112] *P < 0.05 compared with the control group; △ P < 0.05 compared with the model group

[0113] (4) Inflammatory factor levels

[0114] For the detection of inflammatory factors, two types of factors, anti-inflammatory and pro-inflammatory, were concerned. IL-4 is an anti-inflammatory factor, and TGF-β and TNF-α are typical pro-inflammatory factors. The results suggest that compared with the model group, Example 1 and Example 2 can increase the level of the anti-inflammatory factor IL-4 and decrease the levels of the pro-inflammatory factors TGF-β and TNF-α. The results are shown in Table 5.

[0115] Table 5: Inflammatory factor levels in the serum of golden hamsters ( n = 6) mmol / L

[0116]

[0117] *P < 0.05 compared with the control group; △P < 0.05 compared with the model group

[0118] (5) Results of liver function-related indicators

[0119] Liver function plays an important role in the occurrence and development of hyperlipidemia. By detecting the expression levels of ALT, AST, γ-GT, ALB, and ALP, it was found that Example 1 and Example 2 can significantly decrease ALT, AST, γ-GT, and ALB, playing a role in improving liver function. There was little effect on ALP, and the difference was not statistically significant. The results are shown in Tables 6 and 7.

[0120] Table 6: Levels of ALT, AST, and γ-GT in the serum of golden hamsters ( n = 3)

[0121]

[0122] *P < 0.05 compared with the control group; △P < 0.05 compared with the model group

[0123] Table 7: Levels of ALB and ALP in the serum of golden hamsters ( n = 3)

[0124]

[0125]

[0126] *P < 0.05 compared with the control group; △P < 0.05 compared with the model group

[0127] Obviously, those skilled in the art can make various modifications and variations to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalent technologies, the present invention also intends to include these modifications and variations.

Claims

1. A traditional Chinese medicine composition for preventing and treating hyperlipidemia, characterized in that: The traditional Chinese medicine composition is made from the following raw materials in parts by weight: 10 - 60 parts of Paederia scandens, 5 - 40 parts of Atractylodes lancea, 5 - 40 parts of Hawthorn Fruit, 5 - 40 parts of White Peony Root, and 5 - 30 parts of Honeysuckle Flower.

2. The traditional Chinese medicine composition according to claim 1, wherein: The traditional Chinese medicine composition is made from the following raw materials in parts by weight: 15 - 50 parts of Paederia scandens, 10 - 30 parts of Atractylodes lancea, 10 - 30 parts of Hawthorn Fruit, 10 - 30 parts of White Peony Root, and 10 - 20 parts of Honeysuckle Flower.

3. The traditional Chinese medicine composition according to claim 2, wherein: The traditional Chinese medicine composition is made from the following raw materials in parts by weight: 15 parts of Paederia scandens, 10 parts of Atractylodes lancea, 10 parts of Hawthorn Fruit, 10 parts of White Peony Root, and 10 parts of Honeysuckle Flower.

4. The traditional Chinese medicine composition according to claim 2, wherein: The traditional Chinese medicine composition is made from the following raw materials in parts by weight: 50 parts of Paederia scandens, 30 parts of Atractylodes lancea, 30 parts of Hawthorn Fruit, 30 parts of White Peony Root, and 20 parts of Honeysuckle Flower.

5. The preparation method of the traditional Chinese medicine composition according to any one of claims 1 to 4, characterized in that: The preparation method comprises the following steps: weighing each raw material, pre - treating, extracting, and concentrating.

6. The preparation method of the traditional Chinese medicine composition according to any one of claims 1 to 4, characterized in that: It is prepared by water extraction.

7. Use of the traditional Chinese medicine composition according to any one of claims 1 to 4 or the traditional Chinese medicine composition prepared by the preparation method according to claim 5 in the preparation of a medicament for preventing and treating hyperlipidemia.

8. The use according to claim 7, wherein: The medicament has the effects of promoting blood circulation and nourishing blood, strengthening the spleen and removing turbidity.

9. The use according to claim 7, characterized in that: The medicament is in solid form, semi - solid form or liquid form.

10. The use according to claim 9, characterized in that: The medicament is decoction, granule, paste, tablet, capsule, oral liquid, powder or cut crude drug.

11. The use according to claim 10, characterized in that: The medicament is decoction or granule.

Images